Another risky one but with a new income stream things are looking up for Sun.
Why they did not perform better last year is anyones guess.
I suppose the big boys have been let down before but this time its different .
Take a look - long term holder.....

Bought 50k 2 weeks ago transco; really like the look of SUN, the company is making good progress overall. I'm looking forward to Monday's results report.
kim

Yes KIm,

I agree fully. Its been a long wait for me but best of luck to you - a very intuative buy!!! Why the penny share tipsters havent got hold yet is probably historical.

If only all my holdings could produce results as encouraging as SUN's! Profits doubled, positive results for the 7th year in a row, fantastic. Only a small company, no mention of a dividend that I can see but good enough for me to increase my holding today.
kim

I suspect there are lot of long term holders waiting for a more significant move north. I dont understand why the markets dont appear to warm to sun given the results. Could be historical...

Well it at long last things are hotting up!!!!

This share is bit of a conundrum; as you say Transco, its price may have been held back by its history. It is a different company to what it was years ago but who knows, we may one day see a return to 2.50 +! The problem for investors is simple really, a) go for a quick profit, this is more of a possibility now, b) wait until dividends become payable before taking the plunge, c) invest now for capital to grow.

The problem with a) is obvious - it might not happen! with b) the share price will probably have risen considerably by then, so the overall advantage will have been diminished: with c) ? the big IF! IMO I cannot see any way but up for the sp, the progress of this company has been slow, but more importantly, steady and so far, relentless. The risk in investing is the same as with most companies of course, anything can happen - I feel it would have to be a pretty big something to derail this company now.

SUN has had inquiries from BAE Systems, Nasa and BNFL about possible industrial uses for its products. The interest follows a 10-year licensing agreement with Rolls-Royce to apply the company's technology to help with the inspection of aero engines. So will institutions take note I wonder?
kim

Kim,

Nice summing up..
It will be interesting to see any follow up buys in the next few days.
3 mill today sound a lot but its small fry really.
Its news of new orders we need now....

Financial Times today 9th Sept reviews Sun in its Week End Share Watch article.
The conclusion of the article written by James Wilson says,
Hanson Westhouse the house broker indicates that Surgical Innovations is set to meet its sales and profit estimates and suggests that the shares are worth 4.5p adding,
The shares held steady last week to close at 3p giving market cap of 8m at that price they look a snip.

i see that Peter Gyllenhammer has bought 15 million of SUN (4%) through his Unions Discount Company of London this week.
He always buys undervalued stock and things move soon afterwards. Up 10 per cent since purchase.
lets see what happens next

Director Deals - Surgical Innovations Group Plc (SUN)
BFN
Prof Michael McMahon, Non Executive Director bought 362,207 shares in the company on the 6th November 2009 at a price of 1.37p. The Director now holds 11,088,281 shares representing 2.97% of the shares in issue.

Been some steady rises recently...

Michael McMahon also purchased 357,142 at 1.40
worth taking another look ?

Well, the last set if Interims were encouraging that's for sure.

Directors bought 5.5 million shares between them today. Positive news to follow ?

Yorkshire Post does is again...

http://www.yorkshirepost.co.uk/businessnews/Surgical-Innovations-prepares-itself-to.5941771.jp

RNS of a US deal not showing on our site yet but the SP reacting very favourably.

TOK -

Contract win with leading US Group Purchasing Organisation
for laparoscopic instrumentation


Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of
innovative medical devices, is pleased to announce that its US Master
Distributor, Surgical Innovations US Inc. ("SI USA"), has signed a three year
agreement with one of the largest Group Purchasing Organisations ("GPO") in the
US, effective from 1 February 2010.


GPOs help hospitals reduce costs by aggregating volume to negotiate favourable
purchasing terms with vendors. The agreement provides an opportunity for SI,
through SI USA, to gain access to the GPO's 2,200 member hospitals in the
US with its Resposable laparoscopic instrumentation portfolio, Logi Range, an
ergonomic system which combines reusable handles with disposable scissor blades
and graspers. This provides surgeons with high quality, but cost effective
instruments, for performing laparoscopic surgery.


Commenting on the agreement, Graham Bowland, Managing Director of Surgical
Innovations Limited, said: "This agreement with one of the US's leading GPOs
strengthens SI's strategy of developing the Logi Range brand through our
collaboration with SI USA. The 2,200 member hospitals represent a considerable
proportion of all US hospitals, therefore the agreement provides us with
significant access to the US laparoscopic instrumentation market, which is
estimated to be worth $150 million per annum. We look forward to seeing
substantial sales growth of the Logi Range as member hospitals are introduced to
the brand."

SIs instruments featured on BBC News

http://www.surginno.com/news/

http://news.bbc.co.uk/1/hi/england/bradford/8498910.stm

Final Results.

Highlights

Revenue increased to 4,511,000 (2009: 4,312,000)

Retained profit at Group level lower at 525,000 (2008: 630,000) due principally to unavoidable third party issues, now resolved, which resulted in delay in the delivery of a major industrial devices order prior to year end and a write down of autologous blood transfusion assets, following a strategic review

EBITDA of core operating company increased by 11% to 1,103,000 (2008: 995,000)

Net cash of 1.4 million generated from operating activities

Continuing and significant investment in new product development in laparoscopic instrumentation

Major investment in state-of-art manufacturing facility and clean room

Employees more than doubled to reflect increased demand for products

Successfully launched LogiFlex to assist with the accurate placement of gastric bands

New laparoscopic training centre operational during the year and officially opened by Lord Davies of Abersoch, Minister for Trade Investment and Small Business

Largest ever order for industrial devices based on core technology

Negotiations during the year with major US Group Purchasing Organisation (GPO), Premier, successfully concluded in January 2010

Some huge SP movements North recently

Article from the yourkshire post...

http://www.yorkshirepost.co.uk/businessnews/Keyhole-surgery-firm-eyes-US.6198041.jp

Been some nice steady rises

One to tuck away in your bottom drawer!!

Yes I've held these since April 2000!

Ive been in since heaeomecell way before 2000!!!!!!!!!!!!!

since 1993, before heaeomecell was introduced!

before big bang and the begining of time!!

Its been a grim wait to be honest.... this particular rise is down to press comment in the YEP!! nothing more - dont expect any fireworks any time soon!!

I was suprised to see they were still in existence. I can't remember exactly what I paid form them, but looking at a 10year chart, I guess somewhere near where they are now!

Skinny - They have been a rubbish investment although im sure the guys working there have lived the high life with trips overseas and stuff.
I wait and wait and wait!!!!!!!!!!!!!

Well the long term chart is up... Its been a long slow investment yest but its looking its turning around this could be the year for SUN

What a day !!!

Another great start

Surgical Innovations delivers major industrial order


Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative surgical devices, is pleased to announce that it has now delivered the 616,000 order to one of its key industrial partners. The order, originally due for completion in December 2009, was delayed as a consequence of third party technical difficulties, which were resolved in March 2010. This is the largest single order the Group has received within its industrial division.

No big deal when you look at the numbers!
The wait continues butthey normally fall back from here!!

Press Release
28 May 2010




Surgical Innovations Group plc


("SI" or "the Group")


Surgical Innovations wins five year contract with Teleflex Medical


Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, is pleased to announce a five year worldwide contract with Teleflex Medical ("Teleflex"), the designer, manufacturer and distributor of medical devices for critical care and surgical applications. The substantial contract is for the production of articulating handles with bespoke laparoscopic instrumentation.



Building upon a previous relationship, Teleflex approached SI to develop new handle technology. The articulating reusable handles have been under development by Teleflex and SI for two years and the unique, flexible nature improves the ergonomics and ease of use for surgeons performing keyhole surgery. SI retains the full intellectual property rights for the devices, subject to the rights of Teleflex to utilise the IP in the sale of the devices pursuant to the Supply Agreement. The initial roll out of the technology will be throughout Europe with the potential for expansion into the US.



Commenting on the agreement, Graham Bowland, Chief Executive Officer of SI, said: "This order represents an important milestone for our OEM business. We have been working successfully with Teleflex for more than 10 years and we are delighted to continue this successful relationship. Our in-house design, prototype and manufacturing facilities allow us to develop new and improved technologies which can be used by Teleflex to provide their surgeons with an innovative, cost effective laparoscopic device. We look forward to continuing our collaboration with Teleflex as we strive to develop new technologies to help surgeons perform less invasive surgeries."



- Ends -

Even the PM has gone to see SUN at work.......

http://www.google.com/hostednews/ukpress/article/ALeqM5j65bbcMYGSUOcAabLYWXgiWfXtYg

Surgical Innovations Group plc
("SI" or "the Group")
FDA Approval for Logi Flex

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of
innovative medical devices, is pleased to announce that it is has received
510(k) clearance from the US Food and Drug Administration ("FDA") for its Logi
Flex device.
This clearance permits the use of Logi Flex in the US market for both gastric
band deployment and other associated bariatric procedures.
Logi Flex is a Resposable articulating instrument which combines both reusable
and disposable elements - the insert is single use and the handle is reusable -
to offer surgeons a high quality and cost effective solution.
The device has a sterile insert which allows surgeons to fix gastric bands
around the top of a patient's stomach. It also has a unique slot design which
provides a positive grip on the suture allowing the band to be pulled into
position with the minimum of inconvenience.
It is estimated that 250,000 anti-obesity procedures are performed annually in
the US where obesity affects more than 60 million people, representing the
second largest cause of preventable death.
Graham Bowland, Chief Executive Officer of the Group, said: "We are delighted to
be able to announce this approval which will see the pioneering device now being
sold into the US. The majority of surgical instruments in the US are single
use; however with growing financial constraints being placed on hospital
budgets, procurement managers are continuously looking for cost effective
instrumentation and Logi Flex offers the ideal high quality, cost effective
solution."

All this good news will be reflected in the SP sooner or later!!

Results next Tuesday - I'm not too excited!

They should be good !!

Nar 1, on what do you base your comments ?

Pumben, They are always good

great to see some in depth analysis there....

not that i'm going to add anything more constructive than "am crossing fingers"

Interim Results.

Financial highlights

Revenue increased by 79% to 3.57 million (H1 2009: 1.99 million)

Operating profit increased by 234% to 781,000 (H1 2009: 234,000)

Net cash of 888,000 generated from operating activities

Pre-tax profit increased by 256% to 766,000 (H1 2009: 215,000)

Basic earnings per share of 0.18p (H1 2009: 0.05p)

skinny you forgot cancellation of share premium account with a view to be able to pay dividends in the future - lol

Not bad results

Hmmm - looks like 5p bid may be finally - cleared.

Another reasonable move / volume today. I dug out my original buy details from March 2000 @6.75. I might even break even at some point!

You did better than me, Skinny. I paid 7.25p for my first lot on March 23, 2000. But I've been a steady buyer ever since and my average price is 4.25. I've found that these tend to disappoint around results time. Prelims are due in April. Must make a note to keep a close watch.

According to my old spread sheet, I bought on March 21st. On the same spreadsheet are other gems such as :-Atlantic Caspian @10p, Reflec @4p (although sold in the 30s)
Auther Shaw (are you sure) @between 1p and 15p. Ultrasis @45p and ADVFN @30p.

hey ho!

The sun has got his hat on - highest since 2007 wow..... things are looking up.

RNS Number : 4836Z

Surgical Innovations Group PLC

14 January 2011


For immediate release 14 January 2011

Surgical Innovations Group plc

("SI" or "the Group")

Trading update

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, today announces an update on trading for the year ended 31 December 2010.

SI continued to trade well in the second half of 2010 and early indications for the full year are that the Group has performed in line with market expectations.

Graham Bowland, Chief Executive Officer, said: "SI made good progress in 2010 with its Resposable(R) products and OEM business, while continuing to grow its own branded products. The Group benefits from a strong underlying business and we are cautiously optimistic going forward with a number of additional larger OEM prospects in the pipeline for the year ending 31 December 2011. However these contracts can take longer to materialise and are not guaranteed. The board will keep shareholders updated. "

Preliminary results for the year to 31 December 2010 are due to be released on Tuesday 19 April 2011.

- Ends -

Surgical Innovations Group plc

("SI" or "the Group")

Appointments to the Clinical Advisory Board

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, is pleased to announce the appointment of arthroscopic specialist Mr Jon Conroy and laparoscopic specialist Mr Marco Adamo to its Clinical Advisory Board (CAB) with immediate effect.

Mr Jon Conroy, BSc, MB ChB, FRCS (Eng), FRCS (Tr & Orth), MSc, is a Consultant Orthopaedic Surgeon specialising in joint replacements and arthropscopic, or 'keyhole', surgeries to the hip and knee. Mr Conroy is a member of the British Hip Society, International Society of Hip Arthroscopy, The British Orthopaedic Association and a Fellow of The Royal College of Surgeons of England. He also holds a master's degree in Mechanical Engineering from Leeds University. Mr Conroy has published research in several medical journals and won the GlaxoSmithKlein Orthopaedic Essay Prize in 2005 and the John Fitton Prize for Orthopaedic Specialist Registrars in 2006.

Mr Marco Adamo, MD is a Consultant Surgeon and Bariatric Surgery Lead at the University College London Hospital (UCLH) where he has worked since 2007. He graduated in 1995 with full marks and honours in Palermo, Italy where he also completed his training in general surgery. Since moving to the UK in 2000 he has focused on advanced laparoscopic surgery and laparoscopic bariatric (obesity) surgery. He performed the first single incision laparoscopic sleeve gastrectomy in the UK and also has a specific interest in laparoscopic hernia surgery. As a dedicated trainer in his field he often runs advanced training courses for UK and European surgeons. Mr Adamo is a member of the European Association of Endoscopic Surgery (EAES), British Society for Metabolic and Obesity Surgery (BOMSS), Association of Upper-GI Surgeons (AUGIS) and Association of Laparoscopic Surgeons in UK (ALS) and Italy (SICE).

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "We are very pleased to welcome Jon and Marco to the CAB. Jon's expertise in arthroscopy will be invaluable as we begin to develop minimally invasive surgical devices for this very important market. Marco's appointment will strengthen our specialist bariatric team and significantly add value to the development of devices for this particular area of surgery. Our CAB now consists of nine highly experienced surgeons covering a wide range of specialism and markets."

SUN having another run on reasonable volume.

Up on reasonable volume (for SUN).

Final Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, is pleased to announce its final results for the 12 months ending 31 December 2010.

Financial highlights

-- Revenue increased 55% to GBP7.045 million (2009: GBP4.541 million)

-- Pre-tax profit increased 487% to GBP1.549 million (2009: GBP264,000)

-- Operating margins increased to 22% (2009: 6%)

-- Net cash of GBP2.2 million generated from operating activities

-- Basic earnings per share of 0.48p (2009: 0.14p)

Operational highlights

-- Own brand sales increased 30% to GBP3.852 million (2009: GBP2.956 million); driven by flagship Resposable(R) products

-- OEM revenues increased 71% to GBP2.506 million (2009: GBP1.463 million)

-- Industrial sales boosted by delivery of GBP616,000 order

-- Continued major investment in research and development, plant and manufacturing

Doug Liversidge, Chairman of the Group, said: "The Group has undergone yet another year of transformation, successfully meeting the demands of rapid growth. We have continued to invest heavily in the business while R&D capability has undergone a step-change to speed up new product development and improvements to our existing technology. This has proven to be very appealing to potential OEM customers and as a result we are seeing an influx of enquires for a range of minimally invasive devices. With an already promising start to 2011, we are looking forward with confidence."

Very muted response - oh well, I'll just have to wait another ten years or so.

1 in 10 years!

I have had it for 20 years now!!!! I don't know where is the paper though!

Ten year high today.

Nice chart!

Somewhat different to the 20 year!

Ever so slightly!!!

SUN is shining again today.

Yes - an excellent candle!

And that will be 10p!

The sky's the limit, if you see what I mean?!

RNS Number : 4848F

Surgical Innovations Group PLC

26 April 2011

SURGICAL INNOVATIONS GROUP PLC

DIRECTOR / PDMR SHAREHOLDING

Surgical Innovations Group plc (the "Company") announces that it has received notification that Mr D B Liversidge CBE, Non-Executive Chairman of the Company, on 21(st) April 2011 transferred 1,000,000 ordinary shares of 1p each into Quest Investments Ltd a company owned by him and Mrs Pamela Liversidge, OBE. Following this transaction Mr. Liversidge's beneficial interest in the Company remains unchanged at 6,171,821 ordinary shares representing 1.57 per cent. of the issued share capital.

I am removing ALL my research from here due to the constant personal abuse, defamation and distortions of it posted by:

ptholden

hlyeo98

halifax

blackdown

kimoldfield

cynic


This bunch of abusive retards is the reason MoneyAM will NEVER have a forum worth reading.

I have reported them to support by they do nothing, either because they want to force me to PAY them for the Traders Room or because they are too lazy to do anything. Maybe the people in support are the ones perpetrating the abuse, so as to force people to pay for the premium boards. Either way the service is sh1te and a disgrace to the finance industry. No wonder there is nobody left here apart from morons.

I will continue posting my good research on boards that are run in accordance with FSA and LSE listing rules and the interests of the market, not here where ar5eh0les rule the boards and all decent research is buried under their piles of sh1te.

Issue of Equity.

Close above 10p - AGM on the 20th.

Another tick up here today.

Slow and steady, just how I like it!

Still going up (just).

RNS Number : 8595K

Surgical Innovations Group PLC

22 July 2011


For immediate release 22 July 2011

Surgical Innovations Group plc

("SI" or "the Group")

SI extends distribution agreement with SI US for a further 5 years

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that it has signed a 5 year extension to its agreement with SI US, the Group's exclusive US Master distributor. In order to maintain exclusive rights, SI US has committed to distribute SI branded products to a minimum value of $8.0 million to Surgical Innovations over the 5 year period.

SI US will distribute the Logi(R)Range and LogiCut(R) product range together with the reusable line and has been granted first refusal to all future SI branded products within the agreement period. The Group retains the right to manufacture and distribute all devices under the SI brand in all other markets.

Graham Bowland, Chief Executive Officer of SI, said: "This agreement extension with SI US strengthens the Group's strategy of developing its Resposable(R) portfolio in the strategically important US market and gives us confidence for the future. We look forward to developing our partnership with SI US over the next 5 years."

RNS Number : 1201L

Surgical Innovations Group PLC

27 July 2011


For immediate release 27 July 2011

Surgical Innovations Group plc

("SI" or "the Group")

SI signs exclusive five-year distribution agreement with CareFusion for its new advanced laparoscopic retractor, Pretzel-Flex(R)

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces it has signed heads of terms to enter into a five-year exclusive distribution agreement with CareFusion (NYSE: CFN), a leading, global medical device company, for its new advanced Pretzel-Flex(R) laparoscopic retractor.

Under the distribution agreement, CareFusion has acquired exclusive U.S. rights to Pretzel-Flex(R) for five years. Surgical Innovations will manufacture the device for CareFusion and will be marketed in the U.S. under the CareFusion brand. SI retains the right to manufacture and distribute the device, under the SI brand in all other markets.

The patented Pretzel-Flex(R) has been developed by SI for the effective retraction or repositioning of large organs, such as the liver, to provide proper access and visualisation during complex minimally invasive surgery (MIS). A common use of the device is in the retraction of the liver during a gastric bypass. For this type of operation the liver must be moved (retracted) in order to obtain access to the upper stomach. The Pretzel-Flex(R) makes it much easier for doctors to retract large or swollen livers that are common in obese individuals.

The second-generation innovative design gives added strength to the flexible segment technology that SI originally developed for its leading EndoFlex(R) retractor that was previously licensed to CareFusion. The technology allows the instrument to meet unique surgical challenges by enabling the surgeon to insert the instrument through a small port access system, no more than 5mm, into the abdomen before activating a predetermined shape. The Pretzel-Flex(R) has been so named because its predetermined shape is similar to that of a pretzel.

Greater strength has become a necessary requirement for retractors and SI has met the challenge of creating a retractor that meets the opposing demands for smaller devices, such as 3mm percutaneous instruments, and for the ability to gently reposition organs that have become steadily larger in obese patients over recent years.

Graham Bowland, chief executive officer of SI, said: "This latest agreement with CareFusion affirms a long standing and successful partnership and gives Pretzel-Flex(R) access to an established U.S. sales force that is already well versed with our flex technology."

"The new Pretzel-Flex(R) laparoscopic retractor is a strong, complementary fit with our current portfolio of minimally invasive surgical products", said Jim Leitl, senior vice president and general manager of Medical Specialties, Medical Technologies & Services for CareFusion."

A close above 12 here would be good - interims on 14th September.

Might get there today!

Scorchio!

good day here

Muy scorchio!

Sorry - my mistake - interims were on the 14th LAST September. Still awaiting imminent RNS to give this years date!

(Gasps of horror!) ;o)

Sorry Kim :-) Some reasonable trades have gone through today. Close well above 12.

'S ok Skinny, I've got over the shock now! :o)

Another good sunny day!

24 August 2011

Surgical Innovations Group plc

("SI" or "the Group")

Notice of Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, will announce its results for the six months ended 30 June 2011 on Wednesday 14 September 2011.

An analyst presentation will take place at 9:30 am on 14 September 2011 at the offices of Seymour Pierce Limited, 20 Old Bailey, London, EC4M 7EN.

You were right in the end skinny! :o)

RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011

For immediate release: 1 September 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Development and Pre-Supply Agreement signed with Surgical Innovations Group plc

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement ("the Agreement") with Surgical Innovations Group plc ("Surgical Innovations") (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.

Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.

The development of the internal applicator is a key step in extending the Company's expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company's adhesives, will allow AMS to address this important market with reduced surgical complications.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:

"This agreement combines our formulation and regulatory expertise with Surgical Innovations' applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013."

Graham Bowland, Chief Executive Office of Surgical Innovations added:

"Our agreement with AMS affirms SI's reputation in delivering leading design solutions to OEM customers. The applicator device for AMS is a natural extension to our existing minimally invasive surgical product portfolio and we have already commenced on the design work on a fully disposable device. As part of the agreement SI will retain the full intellectual property rights to the applicator device and will also manufacture it on behalf of AMS."

Half Yearly Report.

RNS Number : 1861O

Surgical Innovations Group PLC

14 September 2011


14 September 2011

Surgical Innovations Group plc

("SI" or "the Group")

Interim Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices for minimally invasive surgery ("MIS"), is pleased to announce its interim results for the six months ended 30 June 2011.

Financial highlights

-- Revenues of GBP3.20 million (H1 2010: GBP3.57 million)

-- Operating profit of GBP514,000 (H1 2010: GBP781,000)

-- Pre-tax profit of GBP474,000 (H1 2010: GBP766,000)

-- GBP1.36 million invested in manufacturing, research and development during the period

-- Gross margins in core MIS business increased to 42% (H1 2010: 35%)

-- Net cash of GBP594,000 generated from operating activities

-- Basic earnings per share of 0.12p (H1 2010: 0.18p)

Operational highlights

-- Current trading is encouraging with strong customer demand across the business

-- SI branded products up 29% to GBP2.05 million (H1 2010: GBP1.59 million)

-- Strong demand from OEM partners for R&D expertise

-- Increased penetration of Resposable(R) products will result in increased demand for high margin disposable parts going forward

-- Development of 3mm instrument range and devices for hip arthroscopy underway

-- Two major new product launches to take place in second half of the year: Pretzel-Flex(TM) and Optical Trocar for YelloPort+plus(R)

Skinny,

what do you think about SUN in light of the report?
DO you hold it?

ahoj - I sold back in June @10.1 having held for (ever) years. I keep watching as I think they are a good company, and will buy back at some point. They have had a reasonably good news flow recently and Graham Bowland seems credible. I believe there was an investor presentation this morning, so maybe worth seeing the outcome.

Surgical Innovations Group PLC

01 November 2011


For immediate release 1 November 2011

Surgical Innovations Group plc

("SI" or "the Group")

SI receives confirmation of successful RGF bid

Surgical Innovations Group (AIM: SUN), the designer and manufacturer of innovative medical devices, is pleased to announce that it has received confirmation from the Department of Business, Innovation and Skills, that it is one of 119 successful bids in the UK in the second round of the Government's GBP1.4 billion Regional Growth Fund.

The Regional Growth Fund (RGF) is a GBP1.4bn fund operating across England from 2011 to 2014. It supports projects and programs that lever private sector investment creating economic growth and sustainable employment. It aims particularly to help those areas and communities currently dependent on the public sector to make the transition to sustainable private sector-led growth and prosperity.

SI has received a conditional offer, subject to due diligence, which has been earmarked for job creation, apprenticeships, training, development of innovative medical devices and manufacturing infrastructure. The quantum of the funding to SI remains confidential at this stage of the process.

As part of the bid process, SI has committed to continue its own program of investment in the business, creating direct jobs and increasing the number of apprenticeships it offers over a three year period.

Commenting on this announcement, Graham Bowland, Chief Executive Officer of SI said:

"This is a significant boost for the Group and we are incredibly pleased that our bid has been successful. This funding will allow us to invest heavily in the business and its future growth through product innovation, manufacturing equipment and employment."

For more information on the Regional Growth Fund please visit: http://www.bis.gov.uk/policies/regional-economic-development/regional-growth-fund

- ends -

Mind the gap.

Surgical Innovations Group plc

("SI" or "the Group")

FDA Approval for Logic™ reusable instrument range

US contract with Premier healthcare alliance


Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of creative solutions for minimally invasive surgery, is pleased to announce that it is has received 510(k) clearance from the US Food and Drug Administration ("FDA") for its Logic™ range of reusable instruments and permits the use of the range in the US market.

The instruments are compatible with the Group's Logic™ Handles, which already have approval in the US, and are currently used with SI's Resposable™ Logi™Range.

Graham Bowland, Chief Executive Officer of the Group, said: "We are delighted to announce the FDA approval of our reusable instruments in the US. The economic drivers away from single use instruments in the US are clear, and our modular instruments are ideally positioned to satisfy current surgical procedure budgets."

The Group is also pleased to announce that its US master dealer, SI USA Inc., has been awarded a contract by the Premier healthcare alliance for the sale of the Group's Resposable™ Logi™Range, and Logic™ range of reusable instruments. The contract will run from 1 April 2012 for three years, with the option to extend a further two years upon the agreement of both parties.

The contract will provide SI with additional access to hospitals and hospital networks across the US, and replaces previous, but more limited, contracts already held with Premier.

Graham Bowland continued: "This latest contract with Premier provides us with much more flexibility in the products we can offer whilst giving us access to hospitals that we were previously unable to approach. This is a very exciting development for the Group and strengthens our position in our largest target market."

Seymour Pierce reiterates Buy TP 14.00p.

Seems fair enough!

RNS Number : 4309X
Surgical Innovations Group PLC
14 February 2012



14 February 2012
Surgical Innovations Group plc
("SI" or "the Group")

Issue of Equity

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that, following the exercise of options a Director and certain senior and former employees yesterday, it has issued and allotted 7,889,000 ordinary shares of 1p each.

Details of the Director's options exercised and resulting shareholding is as follows:-


Number of options
Exercise price
Total shareholding following issue
Total shareholding percentage of enlarged issued share capital
Graham Bowland,
Chief Executive
5,889,000
3,654,546 at 1.7p
2,234,454 at 3.5p
10,417,498
2.64%

Accordingly Application has been made to the London Stock Exchange for the 7,889,000 New Ordinary Shares of 1p each to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur at on 17 February 2012. The new ordinary shares rank pari passu with the existing shares of the Company.

Following Admission the total number of ordinary shares in issue will be 403,091,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.

- Ends -
Enquiries:

Surgical Innovations Group plc
www.sigroupplc.com
Doug Liversidge, Non-Executive Chairman

Graham Bowland, Chief Executive Officer
Tel: +44 (0) 113 230 7597 or graham.bowland@surginno.co.uk

17 February 2012

Surgical Innovations Group plc

("SI" or the "Company")

Directors' Dealings

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that it received notification today on Friday 17 February 2012 Graham Bowland, Chief Executive Officer of the Company, sold 5,889,000 shares at price of 10.5 pence per share.

Following the sale, Graham Bowland is interested in 4,528,498 common shares representing approximately 1.12% of the common shares in issue, and also holds options over 1,400,000 shares.

The sale has been undertaken as a one off transaction for personal reasons, to enable Graham Bowland to make a property purchase. Graham continues to be a significant holder in the Company, and his long term commitment to the business remains unchanged.

- Ends -

15 March 2012

Surgical Innovations Group plc

("SI" or the "Company")

FDA 510(k) approval for reusable PretzelFlex(TM)

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), is pleased to announce that it has received 510(k) clearance from the US Food and Drug Administration ('FDA') for its Reusable PretzelFlex(TM) device.

This clearance permits the use of PretzelFlex(TM) in the US market for organ and tissue retraction. The device is easily inserted through a 5mm laparoscopic port and when deployed, forms the unique pretzel shape by way of patented segment technology. The PretzelFlex(TM) device is noted for its strength and stability to support large organs, which makes it a particularly useful tool in minimally invasive obesity surgery.

At the recent SAGES congress (Society of American Gastrointestinal and Endoscopic Surgeons) in San Diego the PretzelFlex(TM) product attracted significant interest from attending US surgeons. The Board looks forward with confidence to the forthcoming product launch.

Graham Bowland, Chief Executive Officer, commented: "I am delighted we have attained FDA approval for the PretzelFlex(TM) device, especially given the rapturous reception the product received at SAGES. The approval allows us to launch the product into the US market, which we previously stated is a strategically important market for the Company, and further, shows our importance as a leading designer and manufacturer of MIS devices."

- ENDS -

Good!

yawn - need sales now...its been a long long wait but maybe this time!!

Notice of Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), will announce preliminary results for the year ended 31 December 2011 on Tuesday 24 April 2012.

Preliminary Results.

Financial highlights
· Group Revenue increased 7.9% to £7.602m (2010: £7.045m)
· Core MIS business revenue up 18.5% to £7.532m (2010: £6.358m)
· Gross margins in core MIS business increased to 47% (2010: 45%)
· Operating profit increased 11.9% to £1.767m (2010: £1.579m)
· Operating margins increased to 23% (2010:22%)
· Pre-tax profit increased 10% to £1.705m (2010: £1.549m)
· Net cash of £1.775m generated from operating activities
· Basic earnings per share of 0.44p (2010: 0.48p)

Operational highlights
· Revenues from SI branded products up 22.7% to £4.725m (2010: £3.852m); driven by flagship Resposable® products
· Revenues from OEM products up by 12.0% to £2.807m (2010: £2.506m); driven by expanded portfolio of OEM customers
· Strong sales of Resposable® instruments with consumable pull through expected in 2012
· Single use consumable products now represent 52% of total MIS sales (2010: 46%)
· OEM agreement with Advanced Medical Solutions (AMS) for a novel adhesive deployment device
· Continued major investment in research and development, plant and manufacturing

RNS Number : 5290F

Surgical Innovations Group PLC

18 June 2012

Surgical Innovations Group plc

("SI" or the "Company")

US OEM distribution agreement with CareFusion for PretzelFlex(R)

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces that it has signed an eight-year exclusive distribution agreement with CareFusion (NYSE: CFN), a leading, global medical device company, for its new advanced PretzelFlex(R) laparoscopic retractor in the US.

Under the distribution agreement, CareFusion has acquired exclusive US rights to PretzelFlex(R) for eight years. This replaces the existing licensing agreement for the Diamond-Flex(R) which is due to end in 2012 and is based on minimum contracted volumes.

The patented PretzelFlex(R) has been developed by SI for the effective retraction or repositioning of large organs, such as the liver, to provide proper access and visualisation during complex minimally invasive surgery (MIS). A common use of the device is in the retraction of the liver during a gastric bypass. For this type of operation the liver must be moved (retracted) in order to obtain access to the upper stomach. The Pretzel-Flex(R) makes it much easier for doctors to retract large or swollen livers that are common in obese individuals.

The device will be manufactured by Surgical Innovations for CareFusion and it will be marketed in the U.S. under the CareFusion brand. SI retains the right to manufacture and distribute the device, under the SI brand in all other markets, with an SI branded PretzelFlex(R) already successfully launched in Europe.

The PretzelFlex(R) generated significant interest from US surgeons at the recent SAGES congress (Society of American Gastrointestinal and Endoscopic Surgeons) in San Diego, and having received 510(k) clearance from the US Food and Drug Administration ('FDA') in March 2012 this deal ensures continuous revenue streams in an already established market.

Graham Bowland, Chief Executive Officer of SI, said: "Confirmation of this latest agreement with CareFusion affirms a long standing and successful partnership and gives us increased exposure to a growing US market for innovative MIS products."

AGM Statement

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), will hold its Annual General Meeting today at 2:00pm at Clayton Wood House, 6 Clayton Wood Bank, Leeds LS16 6QZ, during which the Chairman, Doug Liversidge CBE, will make the following statement:

"The Group has continued to promote its own SI branded products and encourage OEM relationships in its core market of minimally invasive surgery. We have also continued our investment in product development to ensure a continual stream of innovative products for our distribution network. Significantly we remain on target to launch pre-production devices for hip arthroscopy in the third quarter of 2012.

Since the year end, we have signed an eight-year exclusive distribution agreement with CareFusion (NYSE: CFN), a leading, global medical device company, for our new advanced PretzelFlex(R) laparoscopic retractor in the US.

We remain committed to expanding within the US market and the recent launch of the Vikon branded laparoscopic instrument range for Integrated Medical Systems Inc. providesa further opportunity of gaining traction in this lucrative market.

Encouragingly we are beginning to gain interest in our cost effective devices from the NHS as they continue to face pressures to produce annual savings of GBP20bn. In order to support this NHS activity we recently announced a five year contract extension with our distributor, Elemental Healthcare, worth GBP5m.

We remain confident about the future growth prospects of the business and look forward to reporting on the continuing success of the Group over the remainder of the year."

- ENDS -

Slow progress, but better than no progress!

Grant of options

Surgical Innovations Group plc ("the Company") announces that on 26 June 2012 the Company granted options to subscribe for 9,264,000 ordinary shares of 1p each to executive directors and employees of the Company. All of the options are exercisable between 26 June 2015 and 26 June 2022.

Options granted to the executive directors of the Company are as follows:

Director
Number of options granted
Exercise Price
Graham Bowland
2,500,000
9p
Michael Thornton
2,500,000
1p

The award to Graham Bowland will only vest in full subject to the satisfaction of performance targets. The award to Michael Thornton, at a discounted exercise price of 1p, was agreed at the time of his recruitment and as part of his overall remuneration package.

The company has granted options to management and key employees over 1,990,000 ordinary shares at an exercise price of 9p and to staff over 2,274,000 ordinary shares at an exercise price of 7.2p.

Following the grant of options, there are 16,864,000 options in issue over ordinary shares in the Company, representing 4.2 per cent. of the current issued share capital. The options are exercisable at prices between 1p and 9p per share.

- ENDS -

Interim Results

Financial highlights

· Revenues of £3.02m (H1 2011: £3.20m) - entirely made up of Core MIS business revenue

· Gross margins in core MIS business increased to 44.8% (H1 2011: 41.9%)

· EBITDA* up 10.3% to £976,000 (H1 2011: £885,000)

· Operating profit* up 2.5% to £527,000 (H1 2011: £514,000)

· Pre-tax profit* maintained at £475,000 (H1 2011: £474,000)

· Basic earnings per share* of 0.14p (H1 2011: 0.12p)

· Net cash of £888,000 generated from operating activities* (H1 2011: £594,000)

*adjusted to exclude exceptional costs of £294,000

Operational highlights

· Revenues from SI branded products up 8.9% to £2.13m (H1 2011: £1.95m)

· Revenues from OEM products down 28.5% to £0.89m (H1 2011: £1.24m) - due to timing of key orders expected to fall in H2

· Strong sales of Resposable® instruments with consumable pull through expected in H2 and beyond

· Disposable elements from SI Branded Resposable® lines now represent 64% of total SI branded product sales (Full year 2011: 62%)

· US Distribution agreement with CareFusion for the PretzelFlex® laparoscopic retractor

· FDA approval for the Logic™ range of reusable instruments and PretzelFlex®

· US supply agreement with Integrated Medical Systems for YelloPort+plus™

. Booked orders for the full year already exceed Group turnover for year ended 31 Dec 2011

A buy recommendation in this weeks IC . Surgicals shares trade on 14 times forward
earnings, but that could prove conservative if it hits targets this year.

First PretzelFlex? orders shipped to CareFusion

Surgical Innovations Group plc (AIM: SUN), a designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces it has shipped the first batch of PretzelFlex® devices under the CareFusion distribution agreement with a second batch to be shipped in December.

PretzelFlex® has been developed by Surgical Innovations for the effective elevation or retraction of organs and tissue during MIS procedures to provide better access as well as visualisation of surgical sites. The device has a slim line shaft that can be inserted through a 5mm port access system. Then, once inside the abdomen it forms into the innovative pretzel shape when deployed by the surgeon. The device was granted 510(k) clearance from the US FDA in March 2012.

It's going to be marketed in the US under the CareFusion brand. That smacks of weak selling by the sales director to sacrifice your own brand name, it seems to me.

SI to benefit from £5.05m RGF Grant

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces it has formally signed the Regional Growth Fund ("RGF") Final Grant Offer Letter, worth up to £5.05m to SI in Government funding. The grant will be used to develop a state of the art research and development facility and clinical training centre, with a reasonable expectation of creating over 300 jobs in the Leeds City region over the next 12 years.

Second order of 5mm PretzelFlex? shipped

PretzelFlex 3mm FDA approval

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces that it has received 510(k) clearance from the US Food and Drug Administration ('FDA') for its Reusable 3mm PretzelFlex™ device.

This clearance permits the use of the 3mm PretzelFlex™ in the US market for organ and tissue retraction. The device is easily inserted through a 3mm laparoscopic port and when deployed, forms the unique pretzel shape by way of patented segment technology. The 3mm PretzelFlex™ device combines strength and stability within a significantly reduced profile to support organ retraction through a smaller port incision, which makes it a particularly useful tool in minimally invasive paediatric surgery.

The 3mm PretzelFlex™ is a strategic line extension to the recently launched 5mm PretzelFlex™ (FDA approval for which was announced in March 2012) and complements the SI 3mm YelloPort+plus™ Access system. The Board looks forward with confidence to the forthcoming US product launch.

Graham Bowland, Chief Executive Officer, commented: "I am delighted we have attained FDA approval for the 3mm PretzelFlex™ device. Such technology allows us to access new areas of MIS and enhances SI's reputation as a leader in innovative organ retraction devices."

- ENDS -

This is good.

Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the financial year ended 31 December 2012.

SI saw substantially improved trading across both SI Brand and OEM segments in the second half of 2012, driven by increased product demand resulting in contracted orders for delivery in 2012 of £5.6m. This represents an 85% improvement on first half performance; however due to manufacturing capacity constraints at the existing Leeds facility and a delay in US regulatory approval in the final month of the year, £1m of these orders were recognised as revenue in the first week of the financial year ending 31 December 2013.

As a consequence total revenue reported for the 12 months to 31 December 2012 is now expected to be £7.6m (FY 2011: £7.6m).

Following the strategic decision to promote SI Branded products, which now represent 68% of overall revenues (FY 2011: 62%), gross margins are expected to have improved by three basis points to 50.3% (FY 2011: 47.3%). Adjusted EBITDA for the period is ahead of the previous year at £2.85m (2011: £2.8m).

SI ended the year with short term borrowings of £1.4m against bank facilities provided by HSBC of £2.0m.

Given the revenue recognition of £1m in January 2013, the current financial year has started well and provides a sound platform for the remainder of the current financial year.

The Company will announce its preliminary results for the year ended 31 December 2012 on Tuesday, 9 April 2013.